🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our recently completed meta-analysis comparing conventional RT to SRS for management of spinal metastases just published in the Green Journal! Eric Lehrer, MD Nicholas Zaorsky, MD MS Dan Trifiletti, MD sciencedirect.com/science/articl…

Protocol for the phase III RCT SABR-COMET-3 published online at BMC Cancer, doi.org/10.1186/s12885… which we are re-opening in BC after a short COVID break, with international sites opening soon!

ASCO abstract: Randomised phase II trial suggests pts with LD SCLC might benefit from higher dose of thoracic RT (60Gy in 40Fx BID) compared to standard dose (45Gy in 30Fx BID); median OS 42mo vs 23mo (HR 0.63) #radonc meetinglibrary.asco.org/record/184539/…

Meta-analysis of radiotherapy for prostate cancer: 8 weeks (conventional fractionation) vs 5 weeks (hypofractionation) vs ~1 week (ultra-hypofractionation) of treatment Eric Lehrer, MD Amar Kishan James Yu Dan Trifiletti, MD Tim Showalter Oncology Advance #pcsm #RadOnc

Our paper on the effect of radiotherapy-related lymphopenia on overall survival in patients with lung cancer utilizing image-based data mining is now published online in JTO & JTO CRR doi.org/10.1016/j.jtho… Azadeh Abravan RTphysics Manchester Manchester Cancer Research Centre

ESTRO-ACROP guidelines for Target Volume Definition in #SCLC: -Consider clusters of smaller LNs with SAD < 1 cm. -Consider ipsi SCV if level 2 or 3a involved. -CTV = GTV + 5 mm, particularly in CC direction for nodes. -No adaptive nodal cone-down. #radonc pubmed.ncbi.nlm.nih.gov/32673777/

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel mCRPC Identifies an Excess of Long-term Survivors #VisualAbstract Alberto Bossi Houede Nadine Neeraj Agarwal, MD, FASCO buff.ly/3awcpWw

Red Journal: Article in Press! Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer Deek et al. doi.org/10.1016/j.ijro….

Delighted to present updated data from the PACIFIC trial in unresectable Stage III NSCLC ESMO - Eur. Oncology Durable benefit with durvalumab w years - almost 50% of patients alive - MS reached for the first time and is an unprecedented 47.5 months =major benefit for patients Manchester Cancer Research Centre

Prospective single arm phase II trial of SBRT for oligometastatic NSCLC ➡️ SBRT was delivered after 2-4 mo systemic Tx ➡️ About 40% were treated with TKI ➡️ Sig. improved PFS for pts with complete metabolic response (median 54 mo) ➡️ No G4 tox #radonc lungcancerjournal.info/article/S0169-…

Updated meta-analysis of PORT for completely resected Masaoka stage II/III Thymoma ☑️ n=4746 pts ⬆️ OS with HR=0.68 ⬆️ Similar beneficial effect in stage II and III #radonc jto.org/article/S1556-…

So proud to present our Guidelines for Radiotherapy of Bladder Cancer ➡️ GETUG-AFU Recommendations for planning and delivery of radical radiotherapy for ... sciencedirect.com/science/articl…

Metabolic features can predict response to radical RT for prostate cancer! #PCSM Happy to share our latest work with many thanks to all colleagues and friends Laura Evangelista MD PhD @MarcoFusella doi.org/10.1016/j.ctro…

LUNG-ART trial out in The Lancet Oncology: bit.ly/3J3ZNH1 Postoperative #radiotherapy in IIIA pN2 NSCLC pts - no increase in DFS (HR 0.86, p=0.18) or OS - increase in late G3/4 cardiopulm tox Negative results but huge work by Dr Cécile Le Péchoux from Gustave Roussy #lcsm

A partire da domani 18 e 19 aprile a Castelfranco Veneto (TV) Advanced Uro-Oncology Days Responsabili Scientifici Dott.ri Marco Maruzzo, Angelo Porreca, Matteo Sepulcri. Marco Maruzzo Matteo Sepulcri Programma ed iscrizioni: overgroup.eu/evento/advance…

Grande successo per la 2° edizione del congresso ‘Advanced Uro-Oncology’ a Castelfranco Veneto. Responsabili Scientifici: Dott. Marco Maruzzo, Prof. Angelo Porreca, Dott. Matteo Sepulcri. Marco Maruzzo Angelo Porreca Matteo Sepulcri #Oncologia #Urologia #Radioterapia

Sala gremita a Castelfranco Veneto durante i lavori del 2° giorno di 'Advanced Uro-Oncology'. Un evento dedicato ad oncologi, urologi e radioterapisti con Resp. Scientifici Dott. Marco Maruzzo, Prof. Angelo Porreca, Dott. Matteo Sepulcri. Marco Maruzzo Angelo Porreca Matteo Sepulcri

Individual patient data meta-analysis JTO & JTO CRR of neoadjuvant or perioperative trials in resectable NSCLC shows pCR or MPR with neoadjuvant chemo-immunotherapy associated with improved EFS, similar with or without adjuvant immunotherapy component. jto.org/article/S1556-…

Fully published JTO & JTO CRR our individual patient data meta-analysis on EFS in pts w/ resectable NSCLC treated w/ neoadj Chemo-IO. An effort led by Daniele Marinelli Antonio Nuccio Filippo Gallina on behalf of a young Italian multidisciplinary oncology group bit.ly/3YO1iCU 1/4

Does nodal irradiation explain the negative results of concurrent Chemo-ICI-RT observed in Pacific-2 and Checkmate 73L? Better a 'perioperative like' strategy Chemo-ICI ->ChemoRT->ICI? Novel scenarios for unresectable stage III NSCLC discussed by Antonio Nuccio and Matteo Sepulcri